



WELCOME TO JOIN US

# 2022 Sustainability Summary



# 2022 Sustainability Report

## Sustainable Strategies

Key Performance

Highlights

ISO Certification







# ESG

Strategic Development of TTY Biopharm

## HUMAN

Health Union Motivation Awesomeness Navigation

1 Core

# TTY Sustainable Strategies

3 Main Aspects

7 Material Topics



Government  
Suppliers

### Green transformation

Encourage vendors to adopt green manufacturing and actively support environmental protection and fight against climate change.

Action plans encompassing climate Green operations



Local Communities  
NPOs/NGOs  
Customers

### Health of society

Committed to serve the community with our professional ability, provide medical support for healthier population.

Innovative R&D Healthcare



Employees  
Shareholders & Investors  
Media

### Robust corporate development

Good moral practices and good risk management to create a favourable corporate environment for talent cultivation.

Integrity operations  
Risk Management  
Talent Development



# 2022 Key Performance

## Economy



- Consolidated revenue was **NTD\$5,062 million** in the year 2022 (**6.79%** CAGR for 2015-2022).
- TTY has concentrated on manufacturing. Product Lipo-AB, (a difficult generic drug of Liposome), was successfully entered into US market.
- Complete product lines of vaccine and anesthesia for intensive care.
- **3** new oncology drugs to drive the Company's growth.
- By the end of year 2022, a total of **7 invention patents** have been approved (1 application of invention patent under examination).
- Won a bid for the public-fund influenza vaccine. TTY supplied a total of **1,130,000 vials** of public-fund vaccines and **230,000 vials** of self-pay vaccines in year 2022.

# 2022 Key Performance

## Product



- A total of **130 drug licenses** were valid in year 2022.
- More than **36 pharmaceutical items** were listed in the NHI Pharmaceutical Benefits and Reimbursement Schedule in year 2022.
- By the end of year 2022, **7 valid** invention patents were awarded and **1 application** was under examination.
- By the end of year 2022, **211 valid** trademarks were granted and **13** were under examination.
- Trial drug in full conformity with PIC/S GMP pharmaceutical standard and GDP (Good Distribution Practice).

# 2022 Key Performance

## Governance



- **Top 5%** of TPEX companies in the TWSE Corporate Government Assessment for 7 consecutive years since year 2017.
- **6** Board meetings convened in year 2022, with an attendance rate of **98.15%** (excluding attendance via proxy).
- The average advanced training of board members reached **9.94 hours** in year 2022.
- Board members include **2** female directors and **3** independent directors, showing a diversified and independent governance culture.
- **2** Remuneration Committee meetings in year 2022, with an attendance rate of **100%** on average (excluding attendance via proxy).
- **5** Audit Committee meetings in year 2022, with an attendance rate of **100%** (excluding attendance via proxy).

# 2022 Key Performance

## Environmental



- The Liudu and Chungli factories **saved 163,225.93 kWh** of electricity and **83.08 tonCO<sub>2</sub>e** via 8 electricity-saving measures.
- The chemical oxygen demand (COD) emissions in the water of the Liudu factory was **22.83 times** lower than sewer connection standards.
- The quantity of suspended solids (SS) discharged in the water of the Liudu factory was **98.36 times** lower than sewer connection standards.
- The chemical oxygen demand (COD) emissions in the water of the Chungli factory was **19.80 times** lower than sewer connection standards.
- The quantity of suspended solids (SS) discharged in the water of the Chungli factory was **43.24 times** lower than sewer connection standards.
- The Chungli and Liudu factories achieved **100%** in weekly and monthly waste clearance contractor follow-up audits.



# 2022 Key Performance

## Social



- **64 new employees** joined in year 2022, providing the total to **521 work opportunities**.
- **42.19%** of managerial positions are filled by females, demonstrating our commitment to gender equality in the workplace.
- In year 2022, the average salary of entry-level positions was more than **1.5 times** higher than the local minimum salary.
- In year 2022, the average training time of each employee was **6.82 hours**.
- Free flu vaccines were offered to **632** employees and their relatives in year 2022.
- For a consecutive 15 years since year 2008, a total of **391 interns** have benefited from the Summer Internship Program (SIP).



# Highlights

- ◆ To enhance the disclosure of sustainability, this report publishes corporate governance and the implementation of sustainable development in accordance with the GRI standards, and the indicators of TCFD and SASB industry standards.
- ◆ TTY participates with SDGs 17 sustainable goals and initiatives actions consistent with SDG 1, SDG 3, SDG 4, SDG6, SDG 8, SDG 9, SDG 12, SDG 13, SDG 16 and SDG 17 as the developing path in 2022.
- ◆ TTY was honored as the “Best Companies in the healthcare industry” of the 《Health 2.0 Forum》 in 2022, along with the award as one of the “Best Companies to Work for in Asia” Taiwan Edition hosted by HR Asia in both 2020 and 2022. Meanwhile, TTY won the Platinum Award in the Healthcare Category of the TCSA Taiwan Corporate Sustainability Report in both 2021 & 2022.

# ISO Certification

## ISO 45001

Occupational Health & Safety Management System

Certificate No.: 010-23043-O

## Certificate of Approval

This is to certify that the Occupational Health & Safety Management System

**台灣東洋藥品工業股份有限公司**

TTY Biopharm Company Limited

3F., No. 3-1, Park St., Nangang Dist., Taipei City, Taiwan (R.O.C.)  
No.838, Sec. 1, Zhonghua Rd., Zhongli Dist, Taoyuan City, Taiwan (R.O.C.)

**ISO 45001:2018**

驗證範圍

西藥製造、分包裝、實驗室及運銷作業

Pharmaceutical manufacturing, packaging, laboratory and  
Distribution business

證書生效日期12/30/2022，有效期至12/29/2023 \*


  
**Sanjay Kaushik**  
 Managing Director


\* Subject to compliance with requirements specified in Service Specification & Agreement  
 \* To check the validity of this certificate please visit [www.jas-anz.org/register](http://www.jas-anz.org/register)

QMS Certification Services Pvt. Ltd.  
 APE-1, Station Enclave, 47  
 Regencyendra Colony,  
 Vishwanthpur, Bangalore - 560 022,  
 Karnataka, INDIA  
 e-mail: [qmscp@qmscp.com](mailto:qmscp@qmscp.com)

## ISO 14064-1

### Independent Assurance Opinion

Page 1 of 2

Verification Opinion No.: C601645-2022-AG-TWN-DNV      Issued date: 7 June, 2023

This is to verify initiate reporting of Greenhouse Gas Inventory Management Report (2022) of

**TTY Biopharm Company Limited**

**Scope of Verification**  
 DNV Business Assurance (DNV) has been commissioned by TTY Biopharm Company Limited (the Organization) to perform a verification of the greenhouse gas statements of Greenhouse Gas Inventory Management Report (2022) (hereafter the "Inventory Report") in Taiwan, ROC with respect to the sites listed in Appendix A.  
 The Reporting Boundary for the verification including direct GHG emissions and removals, indirect GHG emissions from imported energy, indirect GHG emissions from transportation, and indirect GHG emissions from products used by the Organization. The further descriptions for the Reporting Boundary listed in Appendix B.

**Verification Criteria and GHG Programme**  
 The verification was performed on the basis of ISO 14064-1:2018 as well as criteria given to provide for consistent GHG emission identification, calculation, monitoring and reporting. The verification was conducted in accordance with ISO 14066:2011, ISO 14065:2020, ISO14064-3:2019

**Verification Opinion**  
 It is DNV's opinion that the Inventory Report (2022), which was published on May 29, 2023 (Ver. 1), is free from material discrepancies in accordance with the verification criteria identified as stated above. The opinion is decided based on the following approaches:  
 - For the Direct (Category 1) and Indirect GHG emissions from imported energy (Category 2), the reliability of the information within the Inventory Report (2022) were verified with reasonable level of assurance.  
 - For the other indirect GHG emissions, the involved information was verified and tested using agreed-upon procedures, AUP, defined in Inventory Report.

Alvin Chen

For the issuing office:  
**DNV Business Assurance Co., Ltd.**  
 2391, No. 293, Sec. 2, Wanhua Rd.,  
 Banqiao District, New Taipei City  
 220, Taiwan

Place and date:  
 Taipei, 7 June, 2023

Management Representative

removals as CO2-e	Source, in
535.3169	TTY Biopharm Company Limited Pharmaceutical Development Center
232.4903	25.2717
767.8072	593.2169
215.7928	618.4886
744.7213	35.3484
81.4213	107.7629
041.9354	-
809.7426	143.1113
city Y. AR6	761.5999

Lack of fulfillment of conditions as set out in the Certification Agreement may render this Certificate Invalid.  
 This Verification Opinion is based on the information made available to us and the engagement conditions detailed above. Hence, DNV cannot guarantee the accuracy or correctness of the information. DNV cannot be held liable by any party relying or acting upon this Verification Opinion.  
 DNV ZMATH-OP-F50, Rev.10, 2023-2



2022  
Sustainability  
Report

**Thank you!**



[www.tty.com.tw](http://www.tty.com.tw)  
3F., No. 3-1, Park St.,  
Nangang Dist., Taipei City